Overview

* Entera Bio reports Q3 2025 net loss of $3.2 mln, with increased operating expenses

Outlook

* Cash reserves expected to support operations through mid-2026

Result Drivers

* Research and development expenses were $1.6 million for the three months ended September 30, 2025, compared to $1.5 million for the same period in 2024, an increase of $0.1 million.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$3.20

Income mln

Q3 $3.30

Operatin mln

g

Expenses

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Entera Bio Ltd ( ENTX ) is $10.00, about 72.6% above its November 13 closing price of $2.74

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)